BiotechTube

YM178

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Impairment

Conditions

Renal Impairment

Trial Timeline

Sep 1, 2008 → Sep 1, 2009

NCT ID
NCT00750620

About YM178

YM178 is a phase 1 stage product being developed by Astellas Pharma for Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00750620. Target conditions include Renal Impairment.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (6)

NCT IDPhaseStatus
NCT00337090Phase 2Completed
NCT01720212Phase 1Completed
NCT01334905Phase 1Completed
NCT00965926Phase 1Completed
NCT00840645Phase 3Completed
NCT00750620Phase 1Completed

Competing Products

20 competing products in Renal Impairment

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23
ASP8825Astellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85